Actinium Pharmaceuticals (ATNM) Cash from Investing Activities (2011 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Cash from Investing Activities of -$2000.0 for Q1 2026, up 81.82% quarter-over-quarter from -$11000.0 in Q1 2024.
Actinium Pharmaceuticals (ATNM) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Cash from Investing Activities for 15 consecutive years, with -$2000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$2000.0; the TTM figure through Mar 2026 stood at -$2000.0 (changed N/A YoY), while the FY2025 annual figure was -$104000.0, down 845.45% from the prior year.
- Cash from Investing Activities grew to -$2000.0 in Q1 2026 per ATNM's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$2000.0 in Q1 2026 and bottomed at -$270000.0 in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$59111.1 across 4 years, with a median of -$30000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 985.71% — and 2024, when it jumped 85.53%.
- Actinium Pharmaceuticals' Cash from Investing Activities stood at -$16000.0 in 2022, then tumbled by 87.5% to -$30000.0 in 2023, then surged by 63.33% to -$11000.0 in 2024, then jumped by 81.82% to -$2000.0 in 2026.
- Business Quant data shows ATNM's Cash from Investing Activities at -$2000.0 in Q1 2026, -$11000.0 in Q1 2024, and -$30000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | -478,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -478,000.00 |
| Jun 30, 2026 | -478,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2024 | -11,000.00 |
| Mar 31, 2024 | -11,000.00 |
| Sep 30, 2023 | -30,000.00 |
| Sep 30, 2023 | -30,000.00 |
| Jun 30, 2023 | -47,000.00 |
| Jun 30, 2023 | -47,000.00 |
| Mar 31, 2023 | -76,000.00 |
| Mar 31, 2023 | -76,000.00 |
| Dec 31, 2022 | -16,000.00 |
| Dec 31, 2022 | -16,000.00 |
| Sep 30, 2022 | -73,000.00 |
| Sep 30, 2022 | -73,000.00 |
| Jun 30, 2022 | -270,000.00 |
| Jun 30, 2022 | -270,000.00 |
| Mar 31, 2022 | -7,000.00 |
| Mar 31, 2022 | -7,000.00 |